Disc Medicine, Inc. (IRON)
NASDAQ • Healthcare
Last close at November 16, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Disc Medicine’s preliminary results for the third fiscal quarter of 2026 topped consensus on EPS, with -$1.53 coming in ahead of the -$1.63 estimate by $0.10, based on results reported November 5, 2026. The quarter’s GAAP net loss narrowed to roughly -$59.5 million, a +5% year-over-year improvement from about -$62.3 million, while EPS improved +14% from -$1.77 a year ago. Profitability remained negative, with operating income around -$64.2 million, and cash generation was also negative as operating cash flow was roughly -$40.2 million. For the next period, consensus calls for EPS of -$1.67 on revenue of $3.7 million.
About Disc Medicine, Inc.
Disc Medicine, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector focused on therapies for red blood cell biology. Trading under the ticker IRON, it works on diseases tied to heme biosynthesis and iron homeostasis. In qualitative terms, Disc Medicine is a clinical-stage biotech.
Today's Snapshot
The day ended with IRON 4.3% lower at 76.59, while its sector was flat.
Trading Volume
Below 10d avg (1.0M)
784.6K
vs S&P 500 Today
Underperforming Market
-2.36%
Updated: November 16, 2026 at 21:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$73.42 - $80.62Buy
- RSI (14)49.12Neutral
- Stochastic %K (14, 3, 3)33.28Neutral
- MACD Level (12, 26)2.95Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.